A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

Clinical trial NCT06615206 · RECRUITING

Trial details

NCT number: NCT06615206
Sponsor: HuidaGene Therapeutics Co., Ltd.
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

MECP2 Duplication Syndrome

Start date: 2024-10-30
Primary completion: 2026-10-31
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.